Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings.
Administration of temozolomide to a 46-year-old man with an invasive aggressive prolactin (PRL)-secreting pituitary neoplasm resulted in improvement of the clinical condition and significant decrease of blood PRL levels. Histologic, immunohistochemical, and electron microscopic study demonstrated marked morphological differences in the tumor exposed to temozolomide compared with the unexposed tumor. Necrosis, hemorrhagic areas, accumulation of connective tissue, focal inflammatory infiltration, and neuronal transformation were seen. Immunohistochemical prognostic indicators showed a reduction in growth potential. Based on the clinical, laboratory, and morphological findings, we recommend temozolomide therapy in patients with pituitary tumors not responding adequately to other treatment options.
Kovacs
Kalman
K
Department of Laboratory Medicine, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada M5B 1W8. kovacsk@smh.toronto.on.ca
Horvath
Eva
E
Syro
Luis V
LV
Uribe
Humberto
H
Penagos
Luis C
LC
Ortiz
Leon D
LD
Fadul
Camilo E
CE
D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008854:Microscopy, Electron; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000648:ultrastructure; D011388:Prolactin / Q000097:blood / Q000378:metabolism; D015175:Prolactinoma / Q000188:drug therapy* / Q000473:pathology / Q000648:ultrastructure; D000077204:Temozolomide; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D011388:Prolactin; D000077204:Temozolomide